304 related articles for article (PubMed ID: 12471615)
1. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
2. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
3. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
4. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
[TBL] [Abstract][Full Text] [Related]
5. FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERβ in normal ovarian tissues.
Zhuandi G; Tuanjie C; Luju L; Abdiryim A; Yingying D; Haoqin L; Suocheng W; Li D
Gene; 2018 Aug; 668():174-181. PubMed ID: 29783074
[TBL] [Abstract][Full Text] [Related]
6. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
7. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
9. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
10. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
11. FSH-FSHR3-stem cells in ovary surface epithelium: basis for adult ovarian biology, failure, aging, and cancer.
Bhartiya D; Singh J
Reproduction; 2015 Jan; 149(1):R35-48. PubMed ID: 25269615
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
13. Tubal origin of 'ovarian' low-grade serous carcinoma.
Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W
Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538
[TBL] [Abstract][Full Text] [Related]
14. mRNA expression pattern of gonadotropin receptors in bovine follicular cysts.
Marelli BE; Diaz PU; Salvetti NR; Rey F; Ortega HH
Reprod Biol; 2014 Dec; 14(4):276-81. PubMed ID: 25454493
[TBL] [Abstract][Full Text] [Related]
15. Protein and mRNA expression of follicle-stimulating hormone receptor and luteinizing hormone receptor during the oestrus in the yak (Bos grunniens).
Huo SD; Chen SE; Long RJ; Yang JT; Lu JX; Zang RX; Zhang TJ; Abudureyimu A; Liu JL; Zhang GH; Zhao YQ; Ma ZR
Reprod Domest Anim; 2017 Jun; 52(3):477-482. PubMed ID: 28181328
[TBL] [Abstract][Full Text] [Related]
16. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
El-Etreby NM; Ghazy AA; Rashad R
J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
[TBL] [Abstract][Full Text] [Related]
17. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
18. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
19. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
20. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]